Business
Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa
HENDERSON, Nev., May 20, 2025--Zura Bio launches TibuSHIELD, a Phase 2 study evaluating tibulizumab in adults with hidradenitis suppurativa.
About this update from Zura Bio Limited
[{"type":"image","alt":"Phase 2 TibuSHIELD study will evaluate tibulizumab in adults with hidradenitis suppurativa (HS).","displaySize":"","headline":null,"caption":"Phase 2 TibuSHIELD study will evaluate tibulizumab in adults with hidradenitis suppurativa (HS).","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1920,"height":657,"url":"https://media.zenfs.com/en/business-wire.com/5b66f53acde32baedbfaf0fff2aa7865"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_lscXorw.BL13MH5PLZ_Dw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMyOTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5b66f53acde32baedbfaf0fff2aa7865","width":960,"height":329},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/uRu63WsNGO9c5dekpCOv7w--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04MjI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5b66f53acde32baedbfaf0fff2aa7865","width":1200,"height":411}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/d0999a863363f7a92746f46243ac59bd"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/5dK5sPvKmW3yQfeg2EdBNw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d0999a863363f7a92746f46243ac59bd","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/u7K75rELnNYoRMUTe_PLdQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/d0999a863363f7a92746f46243ac59bd","width":1024,"height":512}}},{"type":"list","items":[{"val":[{"type":"text","content":"TibuSHIELD has launched with the activation of its first clinical site","length":70,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"This study is the first to evaluate dual inhibition of B-cell activating factor (BAFF) and interleukin-17A (IL-17A) pathways in adults with moderate to severe hidradenitis suppurativa (HS)","length":188,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"TibuSHIELD will assess tibulizumab over a 28-week study period, comprising a 16-week primary efficacy assessment and a 12-week safety follow-up, conducted at clinical sites across the United States, Canada, and Europe, with an optional open-label extension...